Business Wire

NC-AVIOQ

Share

Avioq Announces CE Mark and European Launch of VioOne HIV Profile Supplemental Assay

Avioq, Inc. has received CE Marking (Conformité Européenne ) and has begun marketing their Vio One™ HIV Profile™ Supplemental Assay in the European Union and other CE Mark countries.

The product has also been submitted for FDA approval. “We are pleased to provide the CE Mark HIV Profile™ assay to countries outside the U.S.,” said Chamroen Chetty, CEO of Avioq. Dr. Chetty continues, “We are also looking for distribution partners to expand the global availability.”

The HIV Profile™ is an enzyme-linked immunosorbent assay (ELISA) for confirmation and differentiation of individual antibodies directed to various gene products of HIV-1 (Group M & Group O) and HIV-2 in human serum or plasma that were repeatedly reactive in diagnostic screening procedures. Results can also be used to distinguish recent from longstanding HIV-1 infection for HIV-1 incidence estimation.

About Confirmatory Testing
In 2014, the CDC released a new algorithm for HIV testing. The second step of the algorithm includes a supplemental assay that can detect and differentiate HIV-1 and HIV-2 for confirmation of repeatedly reactive HIV-1/HIV-2 screening results. Historically in the USA, this has been done using an FDA approved Western Blot or IFA assay. The HIV Profile™ assay is an improved, faster and easier alternative with performance that aligns with the algorithm.

About Avioq
Avioq, Inc., located in Research Triangle Park, North Carolina, is a medical device company established to develop and market high-quality immunodiagnostic products. Avioq is committed to working closely with its customers to meet their needs and provide the highest quality service. For more information about the Vio One™ HIV Profile™ Supplemental Assay, visit www.avioq.com .

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com